Interventional medicine specialist BTG plc has set its sights high. Its largest franchise, interventional oncology, reported sales of £75.5m ($112m) for fiscal 2015 and the UK company is aiming to at least triple this figure to $300-400m by 2021. With 2016 already upon us, time is ticking by.
The firm, however, does not plan to cut corners. In an interview with Clinica at BTG’s London headquarters, Russell Hagan,...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?